Cargando…

Deep brain stimulation of the nucleus accumbens in treatment-resistant alcohol use disorder: a double-blind randomized controlled multi-center trial

Treatment resistance in alcohol use disorders (AUD) is a major problem for affected individuals and for society. In the search of new treatment options, few case studies using deep brain stimulation (DBS) of the nucleus accumbens have indicated positive effects in AUD. Here we report a double-blind...

Descripción completa

Detalles Bibliográficos
Autores principales: Bach, Patrick, Luderer, Mathias, Müller, Ulf Joachim, Jakobs, Martin, Baldermann, Juan Carlos, Voges, Jürgen, Kiening, Karl, Lux, Anke, Visser-Vandewalle, Veerle, Bogerts, Bernhard, Kuhn, Jens, Mann, Karl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9908935/
https://www.ncbi.nlm.nih.gov/pubmed/36755017
http://dx.doi.org/10.1038/s41398-023-02337-1
_version_ 1784884459438342144
author Bach, Patrick
Luderer, Mathias
Müller, Ulf Joachim
Jakobs, Martin
Baldermann, Juan Carlos
Voges, Jürgen
Kiening, Karl
Lux, Anke
Visser-Vandewalle, Veerle
Bogerts, Bernhard
Kuhn, Jens
Mann, Karl
author_facet Bach, Patrick
Luderer, Mathias
Müller, Ulf Joachim
Jakobs, Martin
Baldermann, Juan Carlos
Voges, Jürgen
Kiening, Karl
Lux, Anke
Visser-Vandewalle, Veerle
Bogerts, Bernhard
Kuhn, Jens
Mann, Karl
author_sort Bach, Patrick
collection PubMed
description Treatment resistance in alcohol use disorders (AUD) is a major problem for affected individuals and for society. In the search of new treatment options, few case studies using deep brain stimulation (DBS) of the nucleus accumbens have indicated positive effects in AUD. Here we report a double-blind randomized controlled trial comparing active DBS (“DBS-EARLY ON”) against sham stimulation (“DBS-LATE ON”) over 6 months in n = 12 AUD inpatients. This 6-month blind phase was followed by a 12-month unblinded period in which all patients received active DBS. Continuous abstinence (primary outcome), alcohol use, alcohol craving, depressiveness, anxiety, anhedonia and quality of life served as outcome parameters. The primary intention-to-treat analysis, comparing continuous abstinence between treatment groups, did not yield statistically significant results, most likely due to the restricted number of participants. In light of the resulting limited statistical power, there is the question of whether DBS effects on secondary outcomes can nonetheless be interpreted as indicative of an therapeutic effect. Analyses of secondary outcomes provide evidence for this, demonstrating a significantly higher proportion of abstinent days, lower alcohol craving and anhedonia in the DBS-EARLY ON group 6 months after randomization. Exploratory responder analyses indicated that patients with high baseline alcohol craving, depressiveness and anhedonia responded to DBS. The results of this first randomized controlled trial are suggestive of beneficial effects of DBS in treatment-resistant AUD and encourage a replication in larger samples.
format Online
Article
Text
id pubmed-9908935
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-99089352023-02-10 Deep brain stimulation of the nucleus accumbens in treatment-resistant alcohol use disorder: a double-blind randomized controlled multi-center trial Bach, Patrick Luderer, Mathias Müller, Ulf Joachim Jakobs, Martin Baldermann, Juan Carlos Voges, Jürgen Kiening, Karl Lux, Anke Visser-Vandewalle, Veerle Bogerts, Bernhard Kuhn, Jens Mann, Karl Transl Psychiatry Article Treatment resistance in alcohol use disorders (AUD) is a major problem for affected individuals and for society. In the search of new treatment options, few case studies using deep brain stimulation (DBS) of the nucleus accumbens have indicated positive effects in AUD. Here we report a double-blind randomized controlled trial comparing active DBS (“DBS-EARLY ON”) against sham stimulation (“DBS-LATE ON”) over 6 months in n = 12 AUD inpatients. This 6-month blind phase was followed by a 12-month unblinded period in which all patients received active DBS. Continuous abstinence (primary outcome), alcohol use, alcohol craving, depressiveness, anxiety, anhedonia and quality of life served as outcome parameters. The primary intention-to-treat analysis, comparing continuous abstinence between treatment groups, did not yield statistically significant results, most likely due to the restricted number of participants. In light of the resulting limited statistical power, there is the question of whether DBS effects on secondary outcomes can nonetheless be interpreted as indicative of an therapeutic effect. Analyses of secondary outcomes provide evidence for this, demonstrating a significantly higher proportion of abstinent days, lower alcohol craving and anhedonia in the DBS-EARLY ON group 6 months after randomization. Exploratory responder analyses indicated that patients with high baseline alcohol craving, depressiveness and anhedonia responded to DBS. The results of this first randomized controlled trial are suggestive of beneficial effects of DBS in treatment-resistant AUD and encourage a replication in larger samples. Nature Publishing Group UK 2023-02-08 /pmc/articles/PMC9908935/ /pubmed/36755017 http://dx.doi.org/10.1038/s41398-023-02337-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Bach, Patrick
Luderer, Mathias
Müller, Ulf Joachim
Jakobs, Martin
Baldermann, Juan Carlos
Voges, Jürgen
Kiening, Karl
Lux, Anke
Visser-Vandewalle, Veerle
Bogerts, Bernhard
Kuhn, Jens
Mann, Karl
Deep brain stimulation of the nucleus accumbens in treatment-resistant alcohol use disorder: a double-blind randomized controlled multi-center trial
title Deep brain stimulation of the nucleus accumbens in treatment-resistant alcohol use disorder: a double-blind randomized controlled multi-center trial
title_full Deep brain stimulation of the nucleus accumbens in treatment-resistant alcohol use disorder: a double-blind randomized controlled multi-center trial
title_fullStr Deep brain stimulation of the nucleus accumbens in treatment-resistant alcohol use disorder: a double-blind randomized controlled multi-center trial
title_full_unstemmed Deep brain stimulation of the nucleus accumbens in treatment-resistant alcohol use disorder: a double-blind randomized controlled multi-center trial
title_short Deep brain stimulation of the nucleus accumbens in treatment-resistant alcohol use disorder: a double-blind randomized controlled multi-center trial
title_sort deep brain stimulation of the nucleus accumbens in treatment-resistant alcohol use disorder: a double-blind randomized controlled multi-center trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9908935/
https://www.ncbi.nlm.nih.gov/pubmed/36755017
http://dx.doi.org/10.1038/s41398-023-02337-1
work_keys_str_mv AT bachpatrick deepbrainstimulationofthenucleusaccumbensintreatmentresistantalcoholusedisorderadoubleblindrandomizedcontrolledmulticentertrial
AT luderermathias deepbrainstimulationofthenucleusaccumbensintreatmentresistantalcoholusedisorderadoubleblindrandomizedcontrolledmulticentertrial
AT mullerulfjoachim deepbrainstimulationofthenucleusaccumbensintreatmentresistantalcoholusedisorderadoubleblindrandomizedcontrolledmulticentertrial
AT jakobsmartin deepbrainstimulationofthenucleusaccumbensintreatmentresistantalcoholusedisorderadoubleblindrandomizedcontrolledmulticentertrial
AT baldermannjuancarlos deepbrainstimulationofthenucleusaccumbensintreatmentresistantalcoholusedisorderadoubleblindrandomizedcontrolledmulticentertrial
AT vogesjurgen deepbrainstimulationofthenucleusaccumbensintreatmentresistantalcoholusedisorderadoubleblindrandomizedcontrolledmulticentertrial
AT kieningkarl deepbrainstimulationofthenucleusaccumbensintreatmentresistantalcoholusedisorderadoubleblindrandomizedcontrolledmulticentertrial
AT luxanke deepbrainstimulationofthenucleusaccumbensintreatmentresistantalcoholusedisorderadoubleblindrandomizedcontrolledmulticentertrial
AT visservandewalleveerle deepbrainstimulationofthenucleusaccumbensintreatmentresistantalcoholusedisorderadoubleblindrandomizedcontrolledmulticentertrial
AT deepbrainstimulationofthenucleusaccumbensintreatmentresistantalcoholusedisorderadoubleblindrandomizedcontrolledmulticentertrial
AT bogertsbernhard deepbrainstimulationofthenucleusaccumbensintreatmentresistantalcoholusedisorderadoubleblindrandomizedcontrolledmulticentertrial
AT kuhnjens deepbrainstimulationofthenucleusaccumbensintreatmentresistantalcoholusedisorderadoubleblindrandomizedcontrolledmulticentertrial
AT mannkarl deepbrainstimulationofthenucleusaccumbensintreatmentresistantalcoholusedisorderadoubleblindrandomizedcontrolledmulticentertrial